Amicus Therapeutics, Inc. (NASDAQ:FOLD)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Recs

0
Player Avatar ANALYST10 (93.02) Submitted: 7/9/2007 1:59:28 PM : Outperform Start Price: $12.16 FOLD Score: -49.76

Hearing & reading very positive reports on this relatively new (recent IPO)Pharma stock!

Great time to get on the ground-floor of a potential ground-breaking pharmaceutical opportunity.

Should be be hearing good reports from analysts very soon, which will be stock/eye popping time.

Featured Broker Partners


Advertisement